OneCell

Startup OneCell is developing a comprehensive platform for diagnosing cancer.

History

2025: Rostec bought 25% of Vansel

The AIS holding, part of the Rostec state corporation, acquired 25% in the authorized capital of Vansel (OneCell), which develops technologies based on artificial intelligence for the diagnosis of cancer. This became known in mid-February 2025.

According to Rostec, OneCell software analyzes the biomaterials of cancer patients using artificial intelligence, which significantly increases the accuracy of diagnostics. The system is capable of processing up to 20 thousand micrographs per minute in real time.

𝓲

Фото: Rsotech

Rostec CEO Sergei Chemezov noted that Vansel's solutions have been clinically tested and are being implemented in Moscow. The queue for research using these technologies is scheduled until the end of 2025.

The development was tested at the All-Russian Research Institute of Medical Technology and clinical research in leading medical centers in Moscow and St. Petersburg. More than 1 million diagnoses have been made using OneCell software.

The founder of the project, Alexander Ninburg, stressed that in key respects the system surpassed foreign competitors, including Paige AI, Owkin and Proscia. The software received a registration certificate from Roszdravnadzor.

Asker Saidov, General Director of AIS, spoke about plans for the development of digital diagnostics in the field of cancer together with Vansel. The company has a production base and competencies in the field of information technology.

The technology can become the basis of the national digital diagnostic circuit within the framework of the federal project for the digitalization of pathological anatomy, which is discussed in the relevant authorities.

The product line of the AIS holding presents complex computing and telecommunication equipment, as well as specialized software. The company has a wide network of highly intelligent industries and a developed technological infrastructure.^[1]

Notes